Jazz Pharmaceuticals JAZZ Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's accrued expenses?
- Jazz Pharmaceuticals (JAZZ) reported accrued expenses of $1.02B in Q1 2026.
- How has Jazz Pharmaceuticals's accrued expenses changed year-over-year?
- Jazz Pharmaceuticals's accrued expenses decreased by 3.9% year-over-year, from $1.06B to $1.02B.
- What is the long-term trend for Jazz Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's accrued expenses has grown at a 24.0% compound annual growth rate (CAGR), from $352.73M to $1.03B.
- What does accrued expenses mean?
- Expenses that have been incurred but not yet paid.
- How do you interpret accrued expenses?
- Significant fluctuations can indicate changes in operational scale or timing of large periodic payments like annual bonuses.
- How does accrued expenses compare across companies?
- Standard across all industries; levels are typically proportional to the size of the workforce and operational complexity.